甲基原氨酸降低c-Myc,通过降低AKAP12的调节来改善糖尿病和勃起功能障碍
Min Luo1, Zongren Hu2, Ziyu Liu3
1Hunan Engineering Research Center of Internet-Chinese and Western Medicine Collaboration-Health Service, Hunan University of Medicine, Huaihua 418000, Hunan Province, PR China; Department of Rehabilitation Medicine and Health Care, Hunan University of Medicine, Huaihua 418000, Hunan Province, PR China; Department of Nephrology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, PR China.
Diabetes research and clinical practice
|November 15, 2023
概括
甲基原氨酸 (MPD) 通过调节c-Myc/AKAP12通路,有效治疗糖尿病勃起功能障碍 (DMED). 这种天然剂在糖尿病小鼠中改善勃起功能方面表现有前途.
科学领域:
- 生物医学研究生物医学研究
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病是勃起功能障碍 (DMED) 的主要原因之一.
- 了解DMED背后的分子机制对于开发有效治疗方法至关重要.
- 甲基原氨酸 (MPD) 正在研究其在DMED中的治疗潜力.
研究的目的:
- 评估MPD在治疗DMED中的疗效.
- 阐明MPD在DMED中的作用的潜在分子机制.
主要方法:
- 糖尿病小鼠模型是使用链毒素建立的.
- 在体外研究中,高葡萄糖刺激了血管内皮细胞 (VEC) 和光滑肌细胞 (VSMC).
- 在体内和体外评估了MPD疗效,通过光酶报告器和ChIP测定分析了c-Myc/AKAP12相互作用.
主要成果:
- 在DMED小鼠阴茎组织中,c-Myc和AKAP12被上调.
- 在高葡萄糖暴露细胞中的MPD治疗增强了活力,减少了亡,降低了c-Myc/AKAP12和增加了p-eNOS.
- 由于AKAP12过度表达和c-Myc过度表达,MPD的影响被逆转,但通过AKAP12沉默被中和,证实MPD通过抑制AKAP12而起作用.
结论:
- 在糖尿病小鼠中,MPD在改善勃起功能方面表现出显著的有效性.
- MPD的治疗效果通过调节c-Myc/AKAP12通路进行调节.
- MPD代表了DMED治疗的潜在天然治疗剂.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


